

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



吉林省輝南長龍生化藥業股份有限公司

Jilin Province Huinan Changlong Bio-pharmacy Company Limited

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8049)

COMPLETION OF TRAINING OF DIRECTORS

Reference is made to the statement of disciplinary action published by The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) dated 13 June 2023 in relation to, among other things, the public statement involving criticism of each of Mr. Zhang Hong (“**Mr. Zhang**”), Mr. Wu Guo Wen, Mr. Xu Xiang Fu, Mr. Zhang Xiao Guang, Mr. Zhao Bao Gang, Mr. Zhang Yi, Mr. Gao Qi Pin and Ms. Tian Jie (together with Mr. Zhang, collectively, the “**Settlement Directors**”), the directors of Jilin Province Huinan Changlong Bio-pharmacy Company Limited (the “**Company**”).

As directed by the GEM Listing Committee of the Stock Exchange, the Settlement Directors, except Mr. Zhang, shall attend 21 hours of training on regulatory and legal topics and GEM Listing Rules (the “**GLR**”) compliance, including at least three hours on each of (i) directors’ duties; (ii) the Corporate Governance Code; and (iii) the GLR requirements for Chapter 19 (the “**Training**”) within 90 days from the publication of the statement of the disciplinary action, whereas Mr. Zhang shall attend 24 hours of Training within the same deadline.

The Company confirms that the Settlement Directors have completed the Training and provided the Stock Exchange with the Training providers’ written certification of full compliance.

By order of the Board

Jilin Province Huinan Changlong Bio-pharmacy Company Limited

Zhang Hong

Chairman

Jilin Province, the PRC

28 September 2023

As at the date of this announcement, the Board comprises six executive directors, being Zhang Hong, Zhang Xiao Guang, Zhao Bao Gang, Wu Guo Wen, Zhang Yi and Xu Xiang Fu and three independent non-executive directors, being Gao Qi Pin, Bai Jun Gui and Tian Jie.

This announcement, for which the directors of the Jilin Province Huinan Changlong Bio-pharmacy Company Limited collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to Jilin Province Huinan Changlong Bio-pharmacy Company Limited. The directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this announcement misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the “Latest Listed Company Information” page of the Stock Exchange website at www.hkexnews.hk for at least 7 days from the date of its publication.